Because the efficiency of ICIs depends on CTLs’ recognition of MIHC class I antigens presenting tumor antigen-derived peptides, β2M, as a key factor required for the assembly of MHC class I complexes and the stable presentation of tumor antigens, its deficiency may be a common genetic mechanism of resistance to ICB therapy. Here, B2M is linked to neoplasm.